Skip to main content
. Author manuscript; available in PMC: 2016 Sep 1.
Published in final edited form as: Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2015 Feb 13;7(5):722–735. doi: 10.1002/wnan.1336

FIGURE 5.

FIGURE 5

Biomimetic display of influenza hemagglutinin (HA) on HpFn leads to improved protection compared to a traditional trivalent vaccine (TIV) in the presence of adjuvant (Ribi). (a) A transmission electron micrograph showing 1999 (NC) HA genetically fused to HpFn and displayed as the native trimer at the threefold axis of the VLP (HA-np). (b) HA-np provides greater protection than TIV when administered to ferrets challenged with 106.5 EID50 dose of 2007 Bris. Viral titers are reported as 50% tissue culture infectious dose (TCID50). (Reprinted with permission from Ref 53. Copyright 2013 Nature Publishing Group)